Royalty Report: Drugs, Cancer, Biotechnology – Collection: 279370

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279370

License Grant
Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license, including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in the Territory excluding Canada; and (b) Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in Canada.

The exclusivity of the foregoing license shall be subject to the retained right of Licensors and their respective Affiliates to practice the Licensor Technology for the purpose of conducting development, manufacture and commercialization of Target Products in the Territory to the extent expressly contemplated by this Agreement.

License Property
HspE7 shall mean any fusion protein containing (a) a human papilloma virus (HPV) E7 antigen, or an antigenic fragment, mutein or conjugate thereof, and (b) a bacterial stress protein, or a fragment, mutein or conjugate thereof, including, in particular and without limitation, that recombinant DNA derived fusion protein containing 638 amino acids, derived from the 65kDa heat shock protein of mycobacterium bovis var. BCG (Hsp65) coupled at the C-terminus to the E7 protein of human papilloma virus (HPV) type 16.  HspE7 includes nucleic acid sequences and vectors and host cells containing nucleic acid sequences encoding such proteins contained therein.

Licensor Technology shall mean the Licensor Know-How and the Licensor Patent Rights..
Licensor Patent Rights shall mean all Patents that Licensor  Controls as of the Execution Date or during the Term, including, without limitation, Patents that claim Licensor Inventions and/or Joint Inventions, which, in the absence of the license granted to Licensee under this Agreement, would be infringed by the making, using, selling, offer for sale or importation of Target Products in the Territory.  The Agreement lists all Licensor Patent Rights existing as of the Execution Date (Base Patents).

US Patent #6,338,952 – Stress proteins and uses therefor
US Patent #6,335,183 – Stress proteins and uses therefor

Field of Use
HspE7 targets a broad spectrum of human papillomavirus ('HPV') related diseases.

IPSCIO Record ID: 1421

License Grant
The restructured agreement provided for the development and commercialization of the Licensor's pharmaceutical fusion product candidate, HspE7.  Under the restructured terms the Licensor granted an option to develop the first generation HspE7 and a License to develop a second generation HspE7 product. By paying additional fees, the Licensee can exclusively develop the second generation HspE7 product. The Licensee has separate non-exclusive rights to negotiate licenses to the Licensor's CoValTM fusion product candidates for the treatment of cancer and hepatitis C.  The agreement also gives the Licensor the right to discuss, negotiate and execute an alternative agreement with a third-party for the development and commercialization of HspE7 through a license, partnership, joint venture or similar transaction.
License Property
The Licensee can exercise its rights to the first generation of HspE7 by paying a fee, in which case it would also become responsible for event-driven milestones that could result in aggregate payments to the Licensor.  In the original agreement the Licensor was responsible for clinical development expenses related to the recurrent respiratory papillomatosis (RRP) indication.  In the new agreement the Licensor is responsible for the manufacturing and other costs of all indications they develop.

HspE7 is based on the Licensor's recombinant fusion product and is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. The E7 protein is derived from the HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on abnormal cells. HspE7 has been in trials as a novel immunotherapeutic for anal dysplasia (AIN) caused by the human papilloma virus (HPV).

Field of Use
In connection with the first generation of HspE7, the restructured Agreement gives the Licensor the right to develop and commercialize the product for indications other than genital warts, including control of regulatory matters such as U.S. Investigational New Drug applications.

IPSCIO Record ID: 240481

License Grant
University grants to Licensee an exclusive license of University's interest under the Licensed Patents for the purpose of making, having made, manufacturing, importing, using, marketing and selling Licensed Products, solely within the Licensed Field, in the Territory, with the right to grant sublicenses to Affiliates and Sublicensees.
License Property
Licensed Product means any product in the Licensed Field whose manufacture, use or sale in any country would, but for either ownership of or a license under the Licensed Patents, comprise an infringement, including contributory infringement, of one or more Valid Claims in such country.

Licensed Patents means any of the following to the extent that University has, or at any time acquires, the right to grant licenses thereto:
(a)  any patent or patent application which claims priority from any of the following patent applications (a) USSN 07/275,433, filed 11/23/88; (b) USSN 07/864,805, filed 4/7/92; (c) USSN 07/864,866, filed 4/7/92; (d) USSN 07/864,807, filed 4/7/92; including all foreign equivalent patent applications and Patent Cooperation Treaty filings, and all patents issuing therefrom in which University has a property interest.
(b)  the following rights, all to the extent covering inventions to which inventive contributions were made as of May 28, 1992 (solely or jointly) by former University faculty member Craig B. Thompson in the scope of his duties for University and the Howard Hughes Medical Institute: U.S. Patent No. 5,434,131 (the '131 Patent') and/or U.S. Patent No. 5,521,288 (the '288 Patent') and (a) any patent applications or patents issuing therefrom claiming or entitled to priority from an application from which the 131 Patent or 288 patent issued.

5,434,131 – Chimeric CTLA4 receptor and methods for its use
5,521,288 – CD28IG fusion protein

Field of Use
Licensed Field means the Licensee Field as defined in the agreement made by and between the Parties and GI (Genetics Institute) on November 17, 1999. The Parties acknowledge and agree that GI has an exclusive and nonoverlapping license·to the University Patents outside of the Licensed Field.

CTLA4 is a key regulator of the activity of the immune system which 'turns off' the immune system after it has successfully cleared a bacterial or viral infection by blocking the activation of T-cells, the immune cells responsible for activating an immune response. Animal and human studies have suggested that a soluble form of CTLA4 ('CTLA4-Ig') may be useful in treating diseases such as rheumatoid arthritis, multiple sclerosis, lupus, psoriasis and organ transplant.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.